Research
JPMorgan Initiates Coverage on Rhythm Pharmaceuticals With Overweight Rating, $145 Price Target
Rhythm Pharmaceuticals (RYTM) has an average rating of Buy and mean price target of $138.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
$RYTM
